EU/3/04/206: Orphan designation for the treatment of osteosarcoma

Muramyl tripeptide phosphatidyl ethanolamine

Table of contents

Overview

Please note that this product was withdrawn from the Community Register of designated orphan medicinal products in March 2019 at the end of the 10-year period of market exclusivity.

On 21 June 2004, orphan designation (EU/3/04/206) was granted by the European Commission to Immuno-Designed Molecules, SA, France, for muramyl tripeptide phosphatidyl ethanolamine for the treatment of osteosarcoma. Immuno-Designed Molecules, SA changed its name to IDM Pharma, SA in January 2009.

The sponsorship was transferred to Takeda France SAS, France, in August 2013.

Muramyl tripeptide phosphatidyl ethanolamine in has been authorised in the EU as Mepact since 6 March 2009.

Key facts

Active substance
Muramyl tripeptide phosphatidyl ethanolamine
Medicine name
Mepact
Intended use
Treatment of osteosarcoma
Orphan designation status
Expired
EU designation number
EU/3/04/206
Date of designation
21/06/2004
Sponsor
Takeda France SAS
Immeuble Pacific
11-13 cours Valmy
92800 Puteaux
France
Tel. +33 1 46 25 12 51
Fax +33 1 46 97 00 11

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating